Compass Therapeutics, Inc.
CMPX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.44 | 0.82 | 0.20 | -0.02 |
| FCF Yield | -22.58% | -20.51% | -6.49% | -10.65% |
| EV / EBITDA | -2.95 | -3.62 | -13.29 | -1.99 |
| Quality | ||||
| ROIC | -42.94% | -33.51% | -21.17% | -57.07% |
| Gross Margin | 100.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.91 | 0.96 | 0.87 | 0.24 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -10.46% | -18.38% | -61.71% | 21.09% |
| Safety | ||||
| Net Debt / EBITDA | 0.67 | 0.46 | 0.86 | 4.74 |
| Interest Coverage | 0.00 | 0.00 | -17.65 | -221.30 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -789.87 | -648.34 | -194.86 |